Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial

Thorax

Volumn 69, Issue 12, 2014, Pages 1073-1079

  Bilton, Diana ^a   Tino, Gregory ^b   Barker, Alan F ^c   Chambers, Daniel C ^d,e   De Soyza, Anthony ^f   Dupont, Lieven J A ^g   O'Dochartaigh, Conor ^h   Van Haren, Eric H J ⁱ   Vidal, Luis Otero ^j   Welte, Tobias ^k   Fox, Howard G ^l   Wu, Jian ^l   Charlton, Brett ^l  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h MIDDLEMORE HOSPITAL   (New Zealand)

ⁱ Sittard Geleen Heerlen   (Netherlands)

^j Partido de Vicente Lopez Provincia de Buenos Aires ^*  (Argentina)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l Pharmaxis Ltd   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MANNITOL; ANTIINFECTIVE AGENT; EXPECTORANT AGENT;

ADULT; AGED; ARTICLE; BACKACHE; BRONCHIECTASIS; CAUSE OF DEATH; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEMOPTYSIS; HUMAN; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; NON CYSTIC FIBROSIS BRONCHIECTASIS; OXYGEN DESATURATION; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SINUSITIS; SPUTUM ANALYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MUCOCILIARY CLEARANCE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RECURRENT DISEASE; SPUTUM; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EXPECTORANTS; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MANNITOL; MEDICATION ADHERENCE; MIDDLE AGED; MUCOCILIARY CLEARANCE; QUALITY OF LIFE; RECURRENCE; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919692674     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205587     Document Type: Article

References (32)

1. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010;86:493-501.
2. Steinfort DP, Brady S, Weisinger HS, et al. Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 2008;102:574-8.
3. Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005;90:737-40.
4. Chang AB, Masel JP, Boyce NC, et al. Non-CF bronchiectasis: clinical and HRCT evaluation. Pediatr Pulmonol 2003;35:477-83.
5. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulmon Med 2005;12:205-9.
6. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010;193:356-65.
7. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-58.
8. Bye P, Lau E, Elkins M. Pharmacological airway clearance strategies in bronchiectasis. Europena Respir Soc Monogr 2011;52:1071-80.
9. Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005;10:46-56.
10. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38:1071-80.
11. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185:645-52.
12. Daviskas E, Turton JA, Anderson SD, et al. A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis. Eur Respir J 2004;24(Suppl 48):707.
13. Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106:661-7.
14. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105:1831-5.
15. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
16. Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159:1843-8.
17. Daviskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir Med 2010;104:371-7.
18. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999;14:678-85.
19. Daviskas E, Anderson SD, Eberl S, et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001;119:414-21.
20. Daviskas E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology 2007;12:683-91.
21. Goldman MD, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function assessed by forced oscillation in a placebo controlled trial in patients with bronchiectasis. Eur Respir J 2004;24:470-1.
22. Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144:215-25.
23. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial. J Cyst Fibros 2011;10:1-8.
24. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
25. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57:15-9.
26. Hill AT, Welham S, Reid K, et al. British Thoracic Society national bronchiectasis audit 2010 and 2011. Thorax 2012;67:928-30.
27. O'Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-34.
28. Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156(2 Pt 1):536-41.
29. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6.
30. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32.
31. Daviskas E, Anderson SD, Eberl S, et al. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008;31:765-72.
32. Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013;12:367-76.